Australia's INOVIQ jumps on ovarian cancer biomarker license
26/09/2025 01:40
** Australia's INOVIQ IIQ.AX jumps as much as 10% to A$0.44 ** Stock gains 5% so far this week; set for second straight week of gains ** Biotech firm secures exclusive worldwide licence from University of Queensland's commercialisation company UniQuest to develop, commercialise novel exosomal biomarkers for early detection of ovarian cancer ** Around 178,990 shares traded, 1.8x the 30-day average ** IIQ last up 3.8%, trims YTD losses to 19.4% (Reporting by Roshan Thomas in Bengaluru) ((Roshan.Thomas@thomsonreuters.com;))
Recent news on Inoviq
See all newsBrief: Inoviq Posts FY26 Net Loss After Tax A$7.5 Million
Brief: INOVIQ Requests Trading Halt
Brief: INOVIQ Says Peter Gunzburg Elected To Role Of Chairman
Brief: Inoviq Says Chairman David Williams To Step Down At Year-End
Australia's INOVIQ slips to 2-1/2-month low on $6.2 million discounted placement